Study participants were a mixed group of asymptomatic carriers, pregnant women, HIV-positive patients, liver patients, and children. Consistent with previous studies, our data confirmed that anti-HDV-positive patients had more severe disease, especially as regard to liver chemistries, liver function, and fibrosis stage, compared to anti-HDV-negative patients. by real-time PCR using COBAS AmpliPrep/COBAS TaqMan HBV Test, version 2.0 Roche Diagnostics, Mannheim, Germany. HDV RNA quantification was performed with a single-step quantitative reverse transcriptase polymerase chain reaction (RT-PCR), Roche, LightMix kit, Meylan, France. FibroTest/ActiTest (BioPredictive, Paris, France), a noninvasive commercial biomarker of fibrosis, was used and converted to the METAVIR score to categorize fibrosis in chronic hepatitis B according to a 5-stage classification: F0 (no fibrosis), F1 (portal and periportal fibrosis without septa), F2 (portal and periportal fibrosis with rare septa), F3 (numerous septa without cirrhosis), and F4 (cirrhosis). The METAVIR score also categorized activity according to a 4-grade classification: A0 (no activity), A1 (minimal activity), A2 (moderate activity), and A3 (severe activity). ETHICS: AMG-510 Ethical approval was obtained from the Douala General Hospital Ethics committee for research. Statistics Variables were AMG-510 described as mean (standard deviation) or median (interquartile range) if quantitative or as count (percentage) if categorical. We used the Student t test to compare means between AMG-510 groups and the Wilcoxon rank sum test to compare medians between groups. Association between categorical variables was assessed using the %)value /th AMG-510 /thead Age (years)34 (10)35 (10)30 (11)0.008Gender?Female73 (24.8)66 (25.1)7 (22.6)?Male221 (75.1)197 (74.9)24 (77.4)0.76Marital status?Not in couple135 (45.9)119 (45.3)16 (51.6)?In couple159 (54.1)144 (54.7)15 (48.4)0.50Residence?Rural15 (5.1)15 (5.7)0 (0.0)?Urban278 (94.9)247 (94.3)31 (100.0)0.38Insurance?Yes21 (7.1)17 (6.5)4 (12.9)?No273 (92.9)246 (93.5)27 (87.1)0.26Platelets 109/L186 (152C227)189 (157C229)155 (72C194)0.002AST (IU/L)28.9 (20C43)28 (19C38)109 (78C159) 0.0001ALT (IU/L)26 (20C47.3)25 (19C41)109 (52C160) 0.0001PT (%)92 (80C100)95 (84C100)76 (55C86) 0.0001GGT (IU/L)29 (20C42)26 (19C36)67 (41C112) 0.0001HBV DNA (UI/mL)434 (41C3843)518 (55C3843)66 (24C11342)0.29Fibrosis stage?F0127 (46.4)125 (51.0)2 (6.9)?F174 (27.0)72 (29.4)2 (6.9)?F227 (9.9)23 (9.4)4 (13.8) 0.0001?F332 (11.7)17 (6.9)15 (51.7)?F414 (5.1)8 (3.3)6 (20.7)Necroinflammation grade?A0164 (59.9)161 (65.7)3 (10.3)?A154 (19.7)53 (21.6)1 (3.5) 0.0001?A229 (10.6)18 (7.4)11 (37.9)?A327 (9.9)13 (5.3)14 (48.3)Decompensated cirrhosis?No276 (93.9)257 (97.7)19 (61.3)?Yes18 (6.1)6 (2.3)12 (38.7) 0.0001Hepatocellular carcinoma?No286 (97.3)254 (97.7)29 (93.6)?Yes8 (2.7)6 (2.3)2 (6.5)0.20 Open in a separate window HDV: hepatitis delta virus; HBV: hepatitis B computer virus; HBeAg: hepatitis B e antigen; HBe ab: hepatitis B e antibody; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma glutaryl transpeptidase; PT: prothrombin time. Out of the 294 HBV patients, 274 had done noninvasive assessments for liver fibrosis and inflammation (Table 1). Anti-HDV-positive patients had higher liver fibrosis and neuroinflammatory scores ( em P /em ? ?0.0001). Decompensated liver cirrhosis too was associated with anti-HDV positivity ( em P /em ? ?0.0001) (Table 2). Discussion In this cross-sectional study, we investigated the frequency of anti-HDV testing in HBsAg-positive patients, the proportion of anti-HDV antibody positivity in eligible study participants, and then compared characteristics between those who were anti-HDV positive and negative. We found out that 80.5% of HBsAg-positive patients were tested for anti-HDV antibody. Of those tested, 10.5% Nrp2 were anti-HDV antibody positive, who were shown to be significantly associated with more severe liver disease (elevated transaminases, increased necroinflammation, fibrosis, and decompensated cirrhosis) than anti-HDV antibody negative subjects. With 80.5% of HBsAg-positive patients tested for anti-HDV, this was much higher than in most of the literature, be it in Europe or America. In a 13-12 months prospective multicenter study in Greece, anti-HDV testing varied from 57% of HbsAg-positive patients when tested prior to 2003 and 35.3% thereafter in 2013.24 Similarly, in a study involving four tertiary hospitals in London, in one of the centers, only 40% of HBV patients were tested for anti-HDV around the request of a clinician. In the second center, in contrast, there was a reflex laboratory algorithm, which understandably achieved anti-HDV testing on almost all first HbsAg-positive samples. 25 Testing for anti-HDV is usually inappropriately low in the United States. In a retrospective study of all veterans who tested positive for HBsAg from 1999 to 2013, only 8.5% were tested for anti-HDV.26 Low testing rates generally reflect relative inexperience with HDV in general27 or infrequent referral to the appropriate specialist and poor access to HDV testing modalities. Prompt referrals to a gastroenterologist/hepatologist have been shown to be more strongly associated with testing than visits to other specialists such as internists and infectious disease specialists.26 In this study setting, all study participants were reviewed by one of the three resident gastroenterologists, and thus the high proportion of testing for anti-HDV. However, anti-HDV testing is recommended for all those HBV-infected patients.23 The frequency of anti-HDV positivity in this study was 10.5%. From three previous studies around the prevalence of anti-HDV prevalence in Cameroon, the only comparable study to ours had a higher anti-HDV positivity of 17.6% of HBsAg-positive subjects.20 The second study had a very small sample size (6.5% anti-HDV positivity from 31 HBsAg-positive.